These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15548126)

  • 1. Longitudinal analysis of the use of etanercept versus infliximab determined from medical chart audit.
    Abarca J; Malone DC; Armstrong EP; Grizzle AJ; Cohen MD
    J Manag Care Pharm; 2004; 10(6):538-42. PubMed ID: 15548126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA; Klingman D; Hazard E; Ray S
    Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.
    Oladapo A; Barner JC; Lawson KA; Novak S; Rascati KL; Richards KM; Harrison DJ
    J Manag Care Spec Pharm; 2014 Jul; 20(7):657-67. PubMed ID: 24967519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. National and regional dose escalation and cost of tumor necrosis factor blocker therapy in biologic-naïve rheumatoid arthritis patients in US health plans.
    Joyce AT; Gandra SR; Fox KM; Smith TW; Pill MW
    J Med Econ; 2014 Jan; 17(1):1-10. PubMed ID: 24131136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
    Carter CT; Changolkar AK; Scott McKenzie R
    J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low rates of adherence for tumor necrosis factor-α inhibitors in Crohn's disease and rheumatoid arthritis: results of a systematic review.
    Fidder HH; Singendonk MM; van der Have M; Oldenburg B; van Oijen MG
    World J Gastroenterol; 2013 Jul; 19(27):4344-50. PubMed ID: 23885145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation.
    Bonafede MM; Gandra SR; Fox KM; Wilson KL
    J Med Econ; 2012; 15(4):635-43. PubMed ID: 22332705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical impact of switching from infliximab to etanercept in patients with rheumatoid arthritis.
    Laas K; Peltomaa R; Kautiainen H; Leirisalo-Repo M
    Clin Rheumatol; 2008 Jul; 27(7):927-32. PubMed ID: 18414967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ankylosing spondylitis and rheumatoid arthritis: serum levels of TNF-α and Its soluble receptors during the course of therapy with etanercept and infliximab.
    Schulz M; Dotzlaw H; Neeck G
    Biomed Res Int; 2014; 2014():675108. PubMed ID: 24783218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficiency of adalimumab, etanercept and infliximab in rheumatoid arthritis patients: dosing patterns and effectiveness in daily clinical practice.
    Ramírez-Herráiz E; Escudero-Vilaplana V; Alañón-Plaza E; Trovato-López N; Herranz-Alonso A; Morell-Baladrón A; Sanjurjo-Sáez M
    Clin Exp Rheumatol; 2013; 31(4):559-65. PubMed ID: 23710583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dosing patterns and costs of tumor necrosis factor inhibitor use for rheumatoid arthritis.
    Harrison DJ; Huang X; Globe D
    Am J Health Syst Pharm; 2010 Aug; 67(15):1281-7. PubMed ID: 20651319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice.
    Moots RJ; Haraoui B; Matucci-Cerinic M; van Riel PL; Kekow J; Schaeverbeke T; Davis A; Tedeschi MA; Freundlich B; Chang DJ; Singh A
    Clin Exp Rheumatol; 2011; 29(1):26-34. PubMed ID: 21345289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effectiveness of anti-tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: a population-based study.
    Finckh A; Simard JF; Duryea J; Liang MH; Huang J; Daneel S; Forster A; Gabay C; Guerne PA
    Arthritis Rheum; 2006 Jan; 54(1):54-9. PubMed ID: 16385495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden.
    Kristensen LE; Saxne T; Nilsson JA; Geborek P
    Arthritis Res Ther; 2006; 8(6):R174. PubMed ID: 17121678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients.
    Zhang J; Xie F; Delzell E; Yun H; Lewis JD; Haynes K; Chen L; Beukelman T; Saag KG; Curtis JR
    Arthritis Care Res (Hoboken); 2015 May; 67(5):624-32. PubMed ID: 25370912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
    van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
    Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis.
    Cohen G; Courvoisier N; Cohen JD; Zaltni S; Sany J; Combe B
    Clin Exp Rheumatol; 2005; 23(6):795-800. PubMed ID: 16396697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis.
    Hansen KE; Hildebrand JP; Genovese MC; Cush JJ; Patel S; Cooley DA; Cohen SB; Gangnon RE; Schiff MH
    J Rheumatol; 2004 Jun; 31(6):1098-102. PubMed ID: 15170921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate.
    Harley CR; Frytak JR; Tandon N
    Am J Manag Care; 2003 Oct; 9(6 Suppl):S136-43. PubMed ID: 14577718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.